试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-22
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
编号:NCT03058939登记状态:入组前撤回企业 / 申办者:University of Chicago
药物 / 成分:Paclitaxel、Perjeta、Herceptin SC、Tamoxifen
登记的停止原因(原文):Study never activated to enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-22
Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
编号:NCT03325465登记状态:入组前撤回企业 / 申办者:University of Chicago
药物 / 成分:Pembrolizumab、Epacadostat
登记的停止原因(原文):Site decided not to move forward with trial. Study never opened to enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-19
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
编号:NCT03291353登记状态:入组前撤回企业 / 申办者:Michael Boyiadzis
药物 / 成分:pembrolizumab
登记的停止原因(原文):This study has closed due to slow accrual.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-18
Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes
编号:NCT01477476登记状态:入组前撤回企业 / 申办者:University of Colorado, Denver
药物 / 成分:Anakinra、Placebo Comparator
登记的停止原因(原文):funding loss, no data was ever collected
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-18
A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults
编号:NCT01942187登记状态:入组前撤回企业 / 申办者:New York State Psychiatric Institute
药物 / 成分:Aripiprazole、Bupropion、Problem Solving Therapy
登记的停止原因(原文):No participants enrolled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-18
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
编号:NCT02581501登记状态:入组前撤回企业 / 申办者:Stamford Hospital
药物 / 成分:GAX - Gemcitabine, Abraxane and Xeloda
登记的停止原因(原文):Due to no enrollment, Celgene (sponsor) withdrew funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-18
Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery
编号:NCT02809755登记状态:入组前撤回企业 / 申办者:NYU Langone Health
药物 / 成分:4% Lidocaine、Saline
登记的停止原因(原文):While 33 people signed consent, no one was enrolled in the study, because none of these patients developed shoulder pain in the recovery room.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-18
Mechanistic Effects of Colchicine in Patients With Myocardial Infarction
编号:NCT02995512登记状态:入组前撤回企业 / 申办者:NYU Langone Health
药物 / 成分:Colchicine 0.6 mg tablets
登记的停止原因(原文):feasibility
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-18
Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients
编号:NCT03146247登记状态:入组前撤回企业 / 申办者:Diamant Thaci
药物 / 成分:Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
登记的停止原因(原文):recruitment was not started
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-04-18
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
编号:NCT03386838登记状态:入组前撤回企业 / 申办者:Bristol-Myers Squibb
药物 / 成分:Nivolumab、BMS-986205、Cetuximab、Cisplatin
登记的停止原因(原文):Business objectives have changed.
查看官方原始记录 ↗